<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="psp413276" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">2038</journal-id><journal-id journal-id-type="pmc-domain">cptpsp</journal-id><journal-id journal-id-type="publisher-id">PSP4</journal-id><journal-title-group><journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title></journal-title-group><issn pub-type="epub">2163-8306</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11812940</article-id><article-id pub-id-type="pmcid-ver">PMC11812940.1</article-id><article-id pub-id-type="pmcaid">11812940</article-id><article-id pub-id-type="pmcaiid">11812940</article-id><article-id pub-id-type="pmid">39575671</article-id><article-id pub-id-type="doi">10.1002/psp4.13276</article-id><article-id pub-id-type="publisher-id">PSP413276</article-id><article-id pub-id-type="other">PSP-2024-0191</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Exploration of the potential impact of batch&#8208;to&#8208;batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products</article-title><alt-title alt-title-type="right-running-head">Impact of batch variability on PK BE study</alt-title><alt-title alt-title-type="left-running-head">Li et&#160;al.</alt-title></title-group><contrib-group><contrib id="psp413276-cr-0001" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="S">Shuhui</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5200-4754</contrib-id><xref rid="psp413276-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413276-cr-0002" contrib-type="author"><name name-style="western"><surname>Feng</surname><given-names initials="K">Kairui</given-names></name><xref rid="psp413276-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413276-cr-0003" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="J">Jieon</given-names></name><xref rid="psp413276-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413276-cr-0004" contrib-type="author"><name name-style="western"><surname>Gong</surname><given-names initials="Y">Yuqing</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6373-5440</contrib-id><xref rid="psp413276-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413276-cr-0005" contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="F">Fang</given-names></name><xref rid="psp413276-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413276-cr-0006" contrib-type="author"><name name-style="western"><surname>Newman</surname><given-names initials="B">Bryan</given-names></name><xref rid="psp413276-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413276-cr-0007" contrib-type="author"><name name-style="western"><surname>Yoon</surname><given-names initials="M">Miyoung</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3653-3488</contrib-id><xref rid="psp413276-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413276-cr-0008" contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="L">Lanyan</given-names></name><xref rid="psp413276-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413276-cr-0009" contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="L">Liang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0257-9082</contrib-id><xref rid="psp413276-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413276-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>Gobburu</surname><given-names initials="JVS">Jogarao V. S.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8348-4295</contrib-id><xref rid="psp413276-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>jgobburu@rx.umaryland.edu</email></address></contrib></contrib-group><aff id="psp413276-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Center for Translational Medicine, School of Pharmacy</named-content>
<institution>University of Maryland</institution>
<city>Baltimore</city>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">USA</country>
</aff><aff id="psp413276-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research</named-content>
<institution>U.S. Food and Drug Administration</institution>
<city>Silver Spring</city>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Jogarao V. S. Gobburu, Center for Translational Medicine, School of Pharmacy, University of Maryland, 20 North Pine Street, Baltimore, MD 21201, USA.<break/>
Email: <email>jgobburu@rx.umaryland.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>14</volume><issue seq="150">2</issue><issue-id pub-id-type="pmc-issue-id">481911</issue-id><issue-id pub-id-type="doi">10.1002/psp4.v14.2</issue-id><fpage>331</fpage><lpage>339</lpage><history><date date-type="rev-recd"><day>26</day><month>9</month><year>2024</year></date><date date-type="received"><day>18</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>12</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-14 04:25:28.667"><day>14</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">CPT: Pharmacometrics &amp; Systems Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PSP4-14-331.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PSP4-14-331.pdf"/><abstract><title>Abstract</title><p>Batch&#8208;to&#8208;batch variability in inhalation powder has been identified as a potential challenge in the development of generic versions. This study explored the impact of batch&#8208;to&#8208;batch variability on the probability of establishing pharmacokinetic (PK) bioequivalence (BE) in a two&#8208;sequence, two&#8208;period (2&#8201;&#215;&#8201;2) crossover study. A model&#8208;based parametric simulation approach was employed, incorporating batch&#8208;to&#8208;batch variability through the relative bioavailability (RBA) ratio. In the absence of batch variability, recruiting a total of 48 subjects in a 2&#8201;&#215;&#8201;2 crossover study with the reference formulation resulted in a 95% probability of concluding BE. However, this probability decreased to 80% with a 5% batch difference in RBA and further declined to 30% with a 10% batch difference. With a 10% batch difference, the required number of subjects to achieve an 80% probability of concluding BE increased to 84. When considering product differences between the reference and the test formulations, an additional 10% batch difference reduced the study power from 97% to 30% for a T/R bioavailability ratio of 100% in a 2&#8201;&#215;&#8201;2 crossover study with 48 subjects. As a result, the substantial impact of batch&#8208;to&#8208;batch variability on the study power and type I error of the PK BE study may pose significant challenges for the development of generic Advair Diskus due to its degree of PK batch&#8208;to&#8208;batch variability. Therefore, alternative PK BE study designs and guidelines are needed to adequately address the influence of batch&#8208;to&#8208;batch variability in products like Advair Diskus.</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Food and Drug Administration
</institution><institution-id institution-id-type="doi">10.13039/100009210</institution-id></institution-wrap></funding-source><award-id>75F40119C10068</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="9"/><word-count count="5900"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:11.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="PSP413276-cit-2001"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, et al. <article-title>Exploration of the potential impact of batch&#8208;to&#8208;batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2025</year>;<volume>14</volume>:<fpage>331</fpage>&#8208;<lpage>339</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.13276</pub-id><pub-id pub-id-type="pmcid">PMC11812940</pub-id><pub-id pub-id-type="pmid">39575671</pub-id></mixed-citation>
</p></notes></front><body id="psp413276-body-0001"><p>
<boxed-text position="anchor" content-type="box" orientation="portrait"><caption><title>Study Highlights</title></caption><p>
<list list-type="simple" id="psp413276-list-0001"><list-item id="psp413276-li-0001"><p>
<bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
</p></list-item></list>
</p><p>High PK batch&#8208;to&#8208;batch variability in the reference FP and SX was noticed, which could hinder the development of the generics.
<list list-type="simple" id="psp413276-list-0002"><list-item id="psp413276-li-0002"><p>
<bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold>
</p></list-item></list>
</p><p>How much does the batch variability affect the study power with and without product differences?
<list list-type="simple" id="psp413276-list-0003"><list-item id="psp413276-li-0003"><p>
<bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold>
</p></list-item></list>
</p><p>The power was reduced from 95% to 80% with a 5% batch difference and to 30% with a 10% batch difference. Eighty&#8208;four subjects were needed to reach 80% power with a 10% batch difference.</p><p>With 48 subjects, a 10% batch difference could reduce the power from 97% to 30% for a T/R ratio of 100% or inflate the type I error from 0% to 30% for a T/R ratio of 80%.
<list list-type="simple" id="psp413276-list-0004"><list-item id="psp413276-li-0004"><p>
<bold>HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?</bold>
</p></list-item></list>
</p><p>We show that batch&#8208;to&#8208;batch variability substantially alters the BE results and changes the study power, which calls for alternative PK BE study design and guidelines for products like Advair Diskus.</p></boxed-text>
</p><sec id="psp413276-sec-0002"><title>INTRODUCTION</title><p>Asthma and chronic obstructive pulmonary disease (COPD), caused by narrowed airways and inflammation, are the leading obstructive chronic pulmonary diseases. Approximately 1 in 13 Americans have asthma/COPD.<xref rid="psp413276-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Advair Diskus, approved in 2000, is an oral dry powder inhaler (DPI) to treat persistent asthma and COPD for patients &gt;4&#8201;years old whose disease is not controlled by inhaled corticosteroid (ICS) alone.<xref rid="psp413276-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Advair Diskus contains fluticasone propionate (FP) and salmeterol xinafoate (SX) as the active pharmaceutical ingredients that exert the pharmacological effects on the patient's airways, leading to the alleviation of symptoms related to asthma and COPD.</p><p>However, studies have reported up to 40% of PK variability among manufacturing batches of the reference Advair Diskus product.<xref rid="psp413276-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> In a study by Burmeister et&#160;al., a four&#8208;sequence, four&#8208;period (4&#8201;&#215;&#8201;4) crossover study was conducted comparing three batches of the reference Advair Diskus 100&#8201;&#956;g/50&#8201;&#956;g with one batch replicated across two periods. All the between&#8208;batch comparisons failed to demonstrate BE with the geometric mean ratios (GMR) of AUC<sub>inf</sub> and <italic toggle="yes">C</italic>
<sub>max</sub> as low as 78% and 65%, respectively. In contrast, the one batch replicated in two periods was able to demonstrate BE. These results suggest the reason behind the BE failure is the inherent deviation between batches, rather than the random variability between occasions or any aspects of study execution. The reasons for the batch&#8208;to&#8208;batch variability are not fully understood, and batch age does not fully explain it.<xref rid="psp413276-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>The observed PK batch&#8208;to&#8208;batch variability has not raised any clinical concerns thus far, potentially due to the flat exposure&#8211;response curve and the ample safety margin.<xref rid="psp413276-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="psp413276-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="psp413276-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="psp413276-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="psp413276-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Instead, the implication of the PK batch&#8208;to&#8208;batch variability is relevant to the BE assessment using the brand Advair Diskus 100/50 as the reference listed drug (RLD). The brand Advair Diskus, one of the most prescribed brand&#8208;name drugs historically, had data exclusivity till 2005, patent protection for the active moiety till 2010, and patent protection for the Diskus device till 2016.<xref rid="psp413276-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="psp413276-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="psp413276-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="psp413276-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> However, there are only three generics for Advair Diskus available on the market in the US, with the first generic approved in 2019.<xref rid="psp413276-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="psp413276-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="psp413276-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> The limited number of generics could result in a high medication price, which could potentially restrict medication accessibility to asthma/COPD patients, contribute to non&#8208;adherence, and increase disease&#8208;related morbidity and mortality.<xref rid="psp413276-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="psp413276-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="psp413276-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Per the product&#8208;specific guidance (PSG), one of the recommendations to market generics of Advair Diskus is to establish the systemic PK bioequivalence (BE) using a single manufacturing batch each of the test (generic candidate) and the RLD in a two&#8208;sequence two&#8208;period (2&#8201;&#215;&#8201;2) crossover study.<xref rid="psp413276-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Owing to the high PK batch&#8208;to&#8208;batch variability, the PK BE outcomes are dependent on the choice of the RLD batches, which could result in unreliable study results and potentially pose challenges to the generic development of Advair Diskus.<xref rid="psp413276-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>This study evaluated the effects of batch&#8208;to&#8208;batch variability on the probability of concluding BE for a 2&#8201;&#215;&#8201;2 crossover study using a model&#8208;based simulation. The differences in the extent and the rate of bioavailability between the test and the reference formulations were also evaluated on top of batch&#8208;to&#8208;batch variability. The aim is to provide a quantitative assessment of the batch&#8208;to&#8208;batch variability effect on the study power and a better understanding of the relationship between the product characteristics and the BE results.</p></sec><sec sec-type="methods" id="psp413276-sec-0003"><title>METHODS</title><sec id="psp413276-sec-0004"><title>Simulation models</title><p>Population PK models adopted from our previous study were used to simulate the PK BE study for FP and SX.<xref rid="psp413276-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Both models were able to capture the observed mean and variability of the BE&#8208;related metrics adequately.<xref rid="psp413276-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> One of the reference batches from our previous study (denoted as R<sub>1</sub>) was used as the reference formulation in this study to simulate the PK BE studies. The model parameters, BSV and BOV are listed in Tables&#160;<xref rid="psp413276-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="psp413276-supitem-0001" ref-type="supplementary-material">S2</xref> for FP and SX, respectively. The parameters of the comparator formulation (denoted as R<sub>2</sub> or <italic toggle="yes">T</italic>) used in this study are detailed below.</p></sec><sec id="psp413276-sec-0005"><title>Simulation scenarios</title><p>To clarify the simulation framework, the simulation scenarios were compartmentalized into two main categories: (1) reference vs. reference product comparison (denoted as R<sub>1</sub> vs. R<sub>2</sub>), where batch&#8208;to&#8208;batch variability is the sole source of difference; (2) reference vs. test product comparison (denoted as <italic toggle="yes">R</italic> vs. <italic toggle="yes">T</italic>), where on top of batch&#8208;to&#8208;batch variability, the formulation&#8208;related difference: the extent and the rate of absorption ratio between the <italic toggle="yes">T</italic> and <italic toggle="yes">R</italic> formulations were presented (Table&#160;<xref rid="psp413276-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="psp413276-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Description of scenarios.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Category</th><th align="left" valign="bottom" rowspan="1" colspan="1">Scenario</th><th align="left" valign="bottom" rowspan="1" colspan="1">Batch&#8208;to&#8208;batch variability<xref rid="psp413276-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Extent of absorption<xref rid="psp413276-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate of absorption<xref rid="psp413276-note-0003" ref-type="table-fn">
<sup>c</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">BE metric affected</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="2" valign="top" colspan="1">Reference vs. reference</td><td align="left" valign="top" rowspan="1" colspan="1">A</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">B</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub>, AUC same scale</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">Reference vs. test</td><td align="left" valign="top" rowspan="1" colspan="1">C</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">AUC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D<xref rid="psp413276-note-0004" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">AUC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">E</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">F<xref rid="psp413276-note-0005" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub>, AUC different scale</td></tr></tbody></table><table-wrap-foot id="psp413276-ntgp-0001"><fn id="psp413276-note-0001"><label>
<sup>a</sup>
</label><p>Batch&#8208;to&#8208;batch variability was assumed as the deviation in the extent of absorption and was added in the model as the relative bioavailability ratio.</p></fn><fn id="psp413276-note-0002"><label>
<sup>b</sup>
</label><p>Extent of absorption was added as relative bioavailability ratio.</p></fn><fn id="psp413276-note-0003"><label>
<sup>c</sup>
</label><p>Rate of absorption was added as absorption rate constant ratio.</p></fn><fn id="psp413276-note-0004"><label>
<sup>d</sup>
</label><p>D was further subdivided into the batch&#8208;to&#8208;batch variability and the extent of absorption ratio in the same direction and in the opposite direction.</p></fn><fn id="psp413276-note-0005"><label>
<sup>e</sup>
</label><p>F was further subdivided into the batch&#8208;to&#8208;batch variability and the rate of absorption ratio in the same direction and in the opposite direction.</p></fn></table-wrap-foot></table-wrap></sec><sec id="psp413276-sec-0006"><title>Reference vs. reference product</title><sec id="psp413276-sec-0007"><title>A. With no batch&#8208;to&#8208;batch variability</title><p>This scenario is to explore how sample size changes the BE passing rate of a 2&#8201;&#215;&#8201;2 crossover study, providing no batch&#8208;to&#8208;batch variability between R<sub>1</sub> and R<sub>2</sub>. In other words, the two batches are identical or have the same parameters. A total of 12&#8211;96 virtual subjects were tested.</p></sec><sec id="psp413276-sec-0008"><title>B. With batch&#8208;to&#8208;batch variability</title><p>In this study, batch&#8208;to&#8208;batch variability is defined as the deviation in the extent of absorption between batches. The previous study shows that <italic toggle="yes">T</italic>
<sub>max</sub> among the reference batches was similar.<xref rid="psp413276-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> For example, the <italic toggle="yes">T</italic>
<sub>max</sub> of the reference batch 1, batch 2, and batch 3 were 8, 6, and 8&#8201;min, respectively, for FP and 4, 4, and 4&#8201;min, respectively, for SX. The observation supports our assumption that batch variability mainly affects absorption extent instead of absorption rate. To account for batch&#8208;to&#8208;batch variability for the reference product, we introduced a simple batch difference to the models using the relative bioavailability (RBA) ratio of R<sub>2</sub>/R<sub>1</sub>. For example, a batch difference of 10% implies that the RBA ratio of R<sub>2</sub>/R<sub>1</sub> is 90% in the simulation. The bioavailability for R<sub>1</sub> is always assumed to be 1&#8211;100&#8201;&#956;g/50&#8201;&#956;g of FP/SX absorbed for R<sub>1</sub> batch, and the bioavailability for R<sub>2</sub> is 0.9&#8211;90&#8201;&#956;g/45&#8201;&#956;g of FP/SX absorbed for R<sub>2</sub> batch. The BE passing rates of a 2&#8201;&#215;&#8201;2 crossover study were explored using batch differences of 0%, 5%, 10%, 15%, and 20% for the reference vs. reference comparison, considering the sample size of 36, 48, and 60 subjects. The RBA and the sample size are assumed to be the same between FP and SX for all the scenarios.</p></sec></sec><sec id="psp413276-sec-0009"><title>Reference vs. test product</title><sec id="psp413276-sec-0010"><title>C. Extent of absorption: With no batch&#8208;to&#8208;batch variability</title><p>The reference and the test formulation could differ in the extent of absorption, which could affect the T/R point estimates of AUC<sub>inf</sub> and <italic toggle="yes">C</italic>
<sub>max</sub> and consequently determine the BE study results. The difference in the extent of absorption between formulations is represented by the RBA ratio in the simulation model. In this scenario, we examined a range of RBA ratios (from 80% to 100% of the T/R ratio) without considering batch&#8208;to&#8208;batch variability, serving as the standards to compare with the scenarios with batch&#8208;to&#8208;batch variability (scenario D). The bioavailability of <italic toggle="yes">R</italic> is always assumed to be 1&#8211;100&#8201;&#956;g/50&#8201;&#956;g of FP/SX absorbed for the reference formulation. For example, if the T/R RBA ratio is 95%, the bioavailability of <italic toggle="yes">T</italic> is 0.95&#8211;95&#8201;&#956;g/47.5&#8201;&#956;g of FP/SX absorbed for the test formulation.</p></sec><sec id="psp413276-sec-0011"><title>D. Extent of absorption: With batch&#8208;to&#8208;batch variability</title><p>In scenario C, we explored the average difference in the extent of absorption between formulations. However, the extent of absorption of the selected batch of each formulation could deviate from the average due to batch&#8208;to&#8208;batch variability. Therefore, on top of the extent of absorption difference between formulations, the effect of batch&#8208;to&#8208;batch variability on the BE passing rate was investigated. The extent of absorption ratio of 80%&#8211;100% was simulated through the RBA ratio, and for each extent of absorption ratio, batch difference of 0%&#8211;20% was simulated through the RBA ratio. The bioavailability of the reference batch is assumed to be 1&#8211;100&#8201;&#956;g/50&#8201;&#956;g of FP/SX absorbed. The bioavailability of the test batch was influenced by both the extent of the absorption ratio and the batch&#8208;to&#8208;batch variability.</p><p>The extent of the absorption ratio and the batch&#8208;to&#8208;batch variability are two independent sources of deviation that could affect the bioavailability of the test batch. It is practical to classify the simulation into two categories: the extent of absorption ratio and the batch&#8208;to&#8208;batch variability in the same direction and the opposite direction. Since the extent of absorption ratio is assumed to be &#8804;100% here, the test formulation cannot have higher bioavailability than the reference. The same direction is defined as the test batch having a bioavailability no more than the population bioavailability of the test formulation. For example, with the T/R extent of absorption ratio of 90% and the batch difference of 10%, the bioavailability of the test batch is 90%&#8211;10%&#8201;=&#8201;80% of that of the reference batch &#8211; 80&#8201;&#956;g/40&#8201;&#956;g of FP/SX absorbed for the test batch. On the other hand, the opposite direction is defined as the selected test batch having more bioavailability than the population bioavailability of the test product due to batch variability. For example, with a <italic toggle="yes">T/R</italic> ratio of 90% and a batch difference of &#8722;10% (minus denotes the opposite direction), the bioavailability of the test batch is 90% &#8208; (&#8722;10%)&#8201;=&#8201;100% of that of the reference batch &#8211; 100&#8201;&#956;g/50&#8201;&#956;g of FP/SX absorbed for the test batch.</p><p>Scenario E and F are described in the supplemental material (Data S1).</p></sec></sec><sec id="psp413276-sec-0012"><title>Calculation of the BE passing rate</title><p>Five hundred trials were simulated for each scenario. For each simulation, non&#8208;compartmental analysis (NCA) analysis was conducted, followed by BE analysis. <italic toggle="yes">C</italic>
<sub>max</sub> and AUC<sub>inf</sub> were obtained from the NCA analysis using the linear&#8208;log trapezoidal method. Values of AUC<sub>inf</sub> were calculated from AUC<sub>t</sub>&#8201;+&#8201;<italic toggle="yes">C</italic>
<sub>last</sub>/&#955;<sub>z</sub>, where AUC<sub>t</sub> is the area under the curve till the last quantifiable sample, <italic toggle="yes">C</italic>
<sub>last</sub> is the last quantifiable concentration, and <italic toggle="yes">&#955;</italic>
<sub>
<italic toggle="yes">z</italic>
</sub> is the terminal elimination rate constant calculated from the terminal slope of the log&#8208;linear concentration&#8211;time curve.</p><p>The NCA results were further evaluated by the BE assessment according to the methodology proposed by FDA.<xref rid="psp413276-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Bioequivalence assessment was made based on the general linear model analysis with the fixed effects of treatment, sequence, period, and a random effect of subject&#8208;within&#8208;sequence. The 90% confidence intervals (90% CI) around the AUC<sub>inf</sub> and <italic toggle="yes">C</italic>
<sub>max</sub> GMR point estimates were calculated. The BE of FP or SX was determined based on whether the 90% confidence intervals of both <italic toggle="yes">C</italic>
<sub>max</sub> and AUC<sub>inf</sub> were within the acceptance range of 80.00%&#8211;125.00%. Advair Diskus BE was determined based on the equivalence of both FP and SX in one repetition. The proportion of the 500 trials passing Advair Diskus BE was calculated as the BE passing rate for each scenario. The analysis was implemented in Pumas (2.0).<xref rid="psp413276-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The graphics were generated by R (4.0.2).<xref rid="psp413276-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p></sec></sec><sec sec-type="results" id="psp413276-sec-0013"><title>RESULTS</title><p>A model&#8208;based simulation was used to simulate BE trials for FP and SX. The models adopted from our previous studies were qualified to capture the BE&#8208;related metrics (<italic toggle="yes">C</italic>
<sub>max</sub>, AUC<sub>t</sub>, AUC<sub>inf</sub>) adequately.<xref rid="psp413276-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Six simulation scenarios were divided into two main categories (Table&#160;<xref rid="psp413276-tbl-0001" ref-type="table">1</xref>). For the reference vs. reference comparison (scenario A, B), batch&#8208;to&#8208;batch variability is the only deviation between batches as the rate of absorption and the extent of absorption are counted as the formulation&#8208;related deviation and were considered in the reference vs. test comparison. Scenario A simulates two identical reference batches to obtain the smallest number of subjects needed without batch&#8208;to&#8208;batch variability. Scenario B simulates two reference batches with varying batch&#8208;to&#8208;batch variability to explore the effect of batch variability within the reference formulation. Batch&#8208;to&#8208;batch variability was manifested as the R<sub>2</sub>/R<sub>1</sub> RBA ratio. Scenarios C&#8211;F explore the formulation&#8208;related differences between the reference and test formulation. Scenarios C and D simulate different extents of absorption ratios between the reference and test formulation without and with batch&#8208;to&#8208;batch variability, respectively. The extent of absorption difference was added as the T/R RBA ratio in the model. Scenarios E and F simulate different rates of absorption ratios between formulations without and with batch&#8208;to&#8208;batch variability, respectively. The rate of absorption difference was added as the T/R Ka ratio in the model.</p><sec id="psp413276-sec-0014"><title>Reference&#8208; vs. reference&#8208; product</title><sec id="psp413276-sec-0015"><title>A. With no batch&#8208;to&#8208;batch variability</title><p>When there is no batch&#8208;to&#8208;batch variability between the two reference batches, the BE passing rates for FP, SX, and Advair Diskus in a 2&#8201;&#215;&#8201;2 crossover study with the different number of subjects are shown in Figure&#160;<xref rid="psp413276-fig-0001" ref-type="fig">1</xref>. The passing rate increases with the number of subjects for Advair Diskus, the BE passing rates in a 2&#8201;&#215;&#8201;2 crossover study with 12, 24, and 36 subjects are 0%, 40%, and 80%, respectively (<italic toggle="yes">N</italic>&#8201;=&#8201;12/24/36, R<sub>2</sub>/R<sub>1</sub> (relative bioavailability ratio)&#8201;=&#8201;1, P (BE passing rate)&#8201;=&#8201;0%/40%/80%). Forty&#8208;eight subjects were required to reach a 95% passing rate (<italic toggle="yes">N</italic>&#8201;=&#8201;48, R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;1, P&#8201;=&#8201;95%). This scenario signifies the best case needing the smallest sample size to pass true BE. The passing rate curves for FP and SX overlap, as shown in Figure&#160;<xref rid="psp413276-fig-0001" ref-type="fig">1</xref>. This is expected as the BOV of FP is comparable to that of SX based on our previous study.<xref rid="psp413276-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The passing rate for Advair Diskus is lower than that for either FP or SX. That is because Advair Diskus is determined as bioequivalent only when both FP and SX are equivalent simultaneously. The passing rates of FP AUC<sub>inf</sub>, FP <italic toggle="yes">C</italic>
<sub>max</sub>, SX AUC<sub>inf</sub>, and SX <italic toggle="yes">C</italic>
<sub>max</sub> are shown in Figure&#160;<xref rid="psp413276-supitem-0001" ref-type="supplementary-material">S2</xref>.</p><fig position="float" fig-type="FIGURE" id="psp413276-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>With no batch variability. The BE passing rates for FP (green), SX (orange), and Advair Diskus (purple) with 12&#8211;84 subjects in a two&#8208;way crossover BE study. The two comparators are two reference batches without batch&#8208;to&#8208;batch variability, which are essentially the same batch.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PSP4-14-331-g002.jpg"/></fig></sec><sec id="psp413276-sec-0016"><title>B. With batch&#8208;to&#8208;batch variability</title><p>The BE passing rates with different levels of batch&#8208;to&#8208;batch variability are shown in Figure&#160;<xref rid="psp413276-fig-0002" ref-type="fig">2</xref>. The BE passing rate decreases with batch&#8208;to&#8208;batch variability: with 48 subjects, the BE passing rate was reduced from 95% to 80% with 5% of batch difference (<italic toggle="yes">N</italic>&#8201;=&#8201;48, R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;0.95, P&#8201;=&#8201;80%) and to 30% with 10% of batch difference (<italic toggle="yes">N</italic>&#8201;=&#8201;48, R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;0.9, P&#8201;=&#8201;30%). (Figure&#160;<xref rid="psp413276-fig-0002" ref-type="fig">2</xref>) The passing rate increases with the number of subjects. With 10% of batch difference, the passing rate was 20% for 36 subjects (<italic toggle="yes">N</italic>&#8201;=&#8201;36, R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;0.9, P&#8201;=&#8201;20%), 30% for 48 subjects (<italic toggle="yes">N</italic>&#8201;=&#8201;48, R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;0.9, P&#8201;=&#8201;30%), and 40% for 60 subjects (<italic toggle="yes">N</italic>&#8201;=&#8201;60, R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;0.9, P&#8201;=&#8201;40%). In order to reach an 80% of passing rate, 84 subjects were needed with a 10% batch difference (<italic toggle="yes">N</italic>&#8201;=&#8201;84, R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;0.9, P&#8201;=&#8201;80%) and 320 subjects with a 15% batch difference (<italic toggle="yes">N</italic>&#8201;=&#8201;320, R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;0.85, P&#8201;=&#8201;80%) (Figure&#160;<xref rid="psp413276-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><fig position="float" fig-type="FIGURE" id="psp413276-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>With batch variability. The BE passing rate for Advair Diskus in a two&#8208;way crossover BE study with 36 (solid), 48 (dashed), and 60 (long&#8208;dashed) subjects. The two comparators are two reference batches with 0%&#8211;20% batch&#8208;to&#8208;batch variability.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PSP4-14-331-g003.jpg"/></fig><p>For a batch difference of 20% (R<sub>2</sub>/R<sub>1</sub>&#8201;=&#8201;0.8), the type I error rates for Advair Diskus, FP, and SX are &lt;5%, as shown in Figure&#160;<xref rid="psp413276-fig-0002" ref-type="fig">2</xref> and Figure&#160;<xref rid="psp413276-supitem-0001" ref-type="supplementary-material">S4</xref>. This is because FP or SX can only be determined as equivalent when both AUC<sub>inf</sub> and <italic toggle="yes">C</italic>
<sub>max</sub> are equivalent. When the batch difference is 20%, bioequivalence was concluded in 5% of the trials using either AUC<sub>inf</sub> or <italic toggle="yes">C</italic>
<sub>max</sub> to determine equivalence (Figure&#160;<xref rid="psp413276-supitem-0001" ref-type="supplementary-material">S4</xref>). To conclude equivalence for FP or SX, both AUC<sub>inf</sub> and <italic toggle="yes">C</italic>
<sub>max</sub> need to be equivalent at the same time, and the probability for this is 5%&#8201;&#215;&#8201;5%&#8201;=&#8201;0.25%, assuming independence. Similarly, both FP and SX need to be equivalent at the same time to conclude equivalence for Advair Diskus, and the probability for this is 0.25%&#8201;&#215;&#8201;0.25% =10<sup>&#8722;4</sup>%, assuming independence. Therefore, the type I error rates for Advair Diskus, FP, and SX are &lt;5%.</p></sec></sec><sec id="psp413276-sec-0017"><title>Reference&#8208; vs. test&#8208; product</title><sec id="psp413276-sec-0018"><title>C. Extent of absorption: With no batch&#8208;to&#8208;batch variability</title><p>The effect of the extent of absorption on BE passing rate is shown in Figure&#160;<xref rid="psp413276-fig-0003" ref-type="fig">3</xref> and Table&#160;<xref rid="psp413276-tbl-0002" ref-type="table">2</xref>. With 48 subjects, the probability of concluding BE is 95% with an extent of absorption ratio of 100% (<italic toggle="yes">N</italic>&#8201;=&#8201;48, T/R (T/R extent of absorption ratio)&#8201;=&#8201;1, P&#8201;=&#8201;95%), 80% with a ratio of 95% (N&#8201;=&#8201;48, T/R&#8201;=&#8201;0.95, P&#8201;=&#8201;80%), and 30% with a ratio of 90% (<italic toggle="yes">N</italic>&#8201;=&#8201;48, T/R&#8201;=&#8201;0.9, P&#8201;=&#8201;30%). The passing rate of FP AUC<sub>inf</sub>, FP <italic toggle="yes">C</italic>
<sub>max</sub>, SX AUC<sub>inf</sub>, and SX <italic toggle="yes">C</italic>
<sub>max</sub> are shown in Figure&#160;<xref rid="psp413276-supitem-0001" ref-type="supplementary-material">S5</xref>.</p><fig position="float" fig-type="FIGURE" id="psp413276-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Impact of extent of absorption ratio on BE passing rates. The BE passing rate of Advair Diskus in a two&#8208;way crossover BE study with 48 subjects. The two comparators are the reference and test product, with the extent of absorption ratio of 80%&#8211;100% and the batch variability of 0%&#8211;20%. The extent of absorption ratio and the batch&#8208;to&#8208;batch variability could be in the same direction (a) or the opposite direction (b).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PSP4-14-331-g001.jpg"/></fig><table-wrap position="float" id="psp413276-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Impact of extent of absorption ratio on BE passing rate.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Extent of absorption ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">No batch variability</th><th colspan="4" align="left" valign="bottom" rowspan="1">(A) batch variability in the same direction</th><th align="left" colspan="4" valign="bottom" rowspan="1">(B) batch variability in the opposite direction</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">0%</th><th align="left" valign="bottom" rowspan="1" colspan="1">5%</th><th align="left" valign="bottom" rowspan="1" colspan="1">10%</th><th align="left" valign="bottom" rowspan="1" colspan="1">15%</th><th align="left" valign="bottom" rowspan="1" colspan="1">20%</th><th align="left" valign="bottom" rowspan="1" colspan="1">&#8722;5%</th><th align="left" valign="bottom" rowspan="1" colspan="1">&#8722;10%</th><th align="left" valign="bottom" rowspan="1" colspan="1">&#8722;15%</th><th align="left" valign="bottom" rowspan="1" colspan="1">&#8722;20%</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="char" char="%" valign="top" rowspan="1" colspan="1">97%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">78%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">31%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.5%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">83%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">43%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">95%</td><td align="char" char="%" valign="top" rowspan="1" colspan="1">79%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">32.5%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">94%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">80.5%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">39%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">7%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">90%</td><td align="char" char="%" valign="top" rowspan="1" colspan="1">25.5%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">79%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">95.5%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">81.5%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41.5%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">85%</td><td align="char" char="%" valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">35.5%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">81%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">97%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">83%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">80%</td><td align="char" char="%" valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">28.5%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">82%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">93%</td></tr></tbody></table><table-wrap-foot id="psp413276-ntgp-0002"><fn id="psp413276-note-0006"><p>
<italic toggle="yes">Note</italic>: The corresponding table for Figure&#160;<xref rid="psp413276-fig-0003" ref-type="fig">3</xref>. The extent of absorption ratio is manifested by the relative bioavailability ratio in the model that affects AUC<sub>inf</sub> T/R ratio. The BE passing rate of Advair Diskus in a two&#8208;way crossover BE study with 48 subjects. The two comparators are the reference and test products with the extent of absorption ratio of 80%&#8211;100% and batch variability of 0%&#8211;20% in the same direction as the extent of absorption ratio (A) or in the opposite direction of the extent of absorption ratio (B).</p></fn></table-wrap-foot></table-wrap></sec><sec id="psp413276-sec-0019"><title>D. Extent of absorption: With batch&#8208;to&#8208;batch variability</title><p>The extent of bioavailability of the reference batch is assumed to be 1, and the test batch could differ from the reference batch in both the extent of absorption and batch&#8208;to&#8208;batch variability. The interplay between these two sources of deviations for the test batch is obvious. If both change in the same direction, then the overall effect on study power compounds. If they change in the opposite direction, the overall effect diminishes.</p><p>As shown in Figure&#160;<xref rid="psp413276-fig-0003" ref-type="fig">3a</xref> and Table&#160;<xref rid="psp413276-tbl-0002" ref-type="table">2</xref>, when batch&#8208;to&#8208;batch variability is in the same direction as the extent of absorption ratio, it reduces the power and inflates the type II error for the equivalent T/R ratios. With 48 subjects, BE passing rates for the T/R ratio of 100% with 0%, 5%, 10%, 15%, and 20% of batch difference are 100%, 80%, 30%, 0%, and 0%, respectively. The BE passing rates for the T/R ratio of 95% with 0%, 5%, 10%, 15%, and 20% of batch difference are 80%, 30%, 0%, 0%, and 0%, respectively. Batch&#8208;to&#8208;batch variability does not change the type I errors for the inequivalent T/R ratios&#8212;the BE passing rates for T/R ratios of 0.85 and 0.8 are 0 at all levels of batch variability.</p><p>On the other hand, if the batch&#8208;to&#8208;batch variability is in the opposite direction to the extent of the absorption ratio, it inflates the type I error for the inequivalent T/R ratios (Figure&#160;<xref rid="psp413276-fig-0003" ref-type="fig">3b</xref> and Table&#160;<xref rid="psp413276-tbl-0002" ref-type="table">2</xref>). The BE passing rates for a T/R ratio of 85% with 0%, &#8722;5%, &#8722;10%, &#8722;15%, and&#8201;&#8722;&#8201;20% of batch difference are 0%, 30%, 80%, 100%, and 80%, respectively. The BE passing rates for a T/R ratio of 80% with 0%, &#8722;5%, &#8722;10%, &#8722;15%, and&#8201;&#8722;&#8201;20% of batch difference are 0%, 2%, 30%, 80%, and 95%, respectively. Besides, batch&#8208;to&#8208;batch variability increases the power for the equivalent T/R ratios to some extent: the BE passing rates for a T/R ratio of 90% with 0%, &#8722;5%, &#8722;10%, &#8722;15%, and&#8201;&#8722;&#8201;20% of batch difference are 30%, 80%, 95%, 80%, and 40%, respectively. The BE passing rates for a T/R ratio of 95% with 0%, &#8722;5%, &#8722;10%, &#8722;15%, and&#8201;&#8722;&#8201;20% of batch difference are 80%, 95%, 80%, 40%, and 5%, respectively. The passing rate of FP AUC<sub>inf</sub>, FP <italic toggle="yes">C</italic>
<sub>max</sub>, SX AUC<sub>inf</sub>, and SX <italic toggle="yes">C</italic>
<sub>max</sub> are shown in Figure&#160;<xref rid="psp413276-supitem-0001" ref-type="supplementary-material">S5</xref>.</p><p>The results of scenarios E and F are described in the supplemental material.</p></sec></sec></sec><sec sec-type="discussion" id="psp413276-sec-0020"><title>DISCUSSION</title><p>Pharmaceutical companies usually determine the sample size of a BE study based on the expected T/R ratios of the BE metrics, as the significance level and the BE margins are set by the regulatory guidance, and the within&#8208;subject variability (WSV) is usually invariable. In this study, we demonstrate that batch&#8208;to&#8208;batch variability has a significant impact on the BE results and study power. With a sample size of 48 subjects, a 10% batch difference can reduce the study power from 97% to 30% for a T/R ratio of 100% or inflate the type I error from 0% to 30% for a T/R ratio of 80%. If batch variability is ignored, there may be an increased risk of patients being treated with an inequivalent formulation or pharmaceutical companies not obtaining approval for an equivalent formulation. Even when batch variability is considered, reaching 80% of power would require a large sample size of 320 subjects with a 15% batch difference.</p><p>In this study, a few assumptions were leveraged to compartmentalize the simulation scenarios. First, we defined that the rate and extent of absorption are the same among reference batches, and only batch&#8208;to&#8208;batch variability is present. This scenario is merely to evaluate the effect of batch&#8208;to&#8208;batch variability on the study results, with all the other parameters being the same. Second, the batch&#8208;to&#8208;batch variability affects the extent of absorption between batches, not the rate of absorption, as <italic toggle="yes">T</italic>
<sub>max</sub> was similar among different batches; therefore, batch&#8208;to&#8208;batch variability was added as the R<sub>2</sub>/R<sub>1</sub> RBA ratio in the model with the bioavailability of R<sub>1</sub> kept constant at 1. Next, the reference and test formulation could differ in the extent of absorption and rate of absorption, manifested by the T/R bioavailability ratio and the T/R Ka ratio, respectively. Also, the two formulation&#8208;related differences &#8211; the extent of absorption and rate of absorption were explored separately in this study to avoid overcomplicated scenarios and inferences. Finally, the RBA and sample size are assumed to be the same between FP and SX to simplify the scenarios.</p><p>Our results are similar to that of the previous study conducted by Benet et&#160;al.<xref rid="psp413276-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In their study with 48 subjects, 10% of batch&#8208;to&#8208;batch variability reduced the study power from 100% to 65% for a T/R ratio of 100% and inflated the type I error from 5% to 30% for a T/R ratio of 125%. However, their approach is different from ours. They used a statistical model to simulate PK meterics and added batch&#8208;to&#8208;batch variability as a random parameter. We used a population PK model to simulate a BE trial and added batch&#8208;to&#8208;batch variability as a fixed deviation of the RBA. The consequences and inferences of these two approaches are elaborated in the supplemental material. While both studies could be employed in tandem, our approach potentially offers a more precise representation of the observations. Also, this study provides us a deeper understanding of the relationship between the product characteristics and the study power and how the interplay between the product characteristics and batch&#8208;to&#8208;batch variability changes the study results.</p><p>This study illustrates the implications of whether or not additional care is taken during batch selection and highlights the importance of careful batch selection for products with high batch&#8208;to&#8208;batch variability. While a standard approach for addressing batch&#8208;to&#8208;batch variability remains an open discussion topic, using a representative batch in a PK BE study remains a viable approach for products with high batch&#8208;to&#8208;batch variability. Therefore, future research is warranted to explore and validate study designs and approaches to aid proper batch selection. The MIDD approach has played a critical role in generic drug development. It has been used to determine appropriate BE end points, inform efficient BE study design, and support the BE guidelines and analysis for complex drug products.<xref rid="psp413276-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="psp413276-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="psp413276-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Leveraging the MIDD approach to explore alternative study designs and criteria to aid batch selection for products with batch&#8208;to&#8208;batch variability could be studied in the future.<xref rid="psp413276-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="psp413276-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</p></sec><sec sec-type="conclusions" id="psp413276-sec-0021"><title>CONCLUSION</title><p>This study underscores the challenges posed by high batch&#8208;to&#8208;batch variability in PK BE studies for products like Advair Diskus. Even a minor 10% bioavailability difference among reference batches can substantially impact the statistical power, reducing it from 97% to 30% when considering a T/R ratio of 100%. This research advocates for future exploration of alternative PK BE study designs that can provide additional options for effectively addressing the impacts of batch&#8208;to&#8208;batch variability. Furthermore, fostering collaboration and communication through pre&#8208;ANDA meetings between pharmaceutical companies and regulators during the early stages of generic drug development could potentially facilitate the development of future guidelines to address this issue.</p></sec><sec id="psp413276-sec-0022"><title>AUTHOR CONTRIBUTIONS</title><p>S.L. wrote the manuscript, designed the research, performed the research, and analyzed the data. J.V.S.G. wrote the manuscript, designed the research, and performed the research. J.L., F.W., M.Y., L.F., and L.Z. designed the research. K.F., Y.G., and B.N. wrote the manuscript and designed the research.</p></sec><sec id="psp413276-sec-0024"><title>FUNDING INFORMATION</title><p>This work is supported by the grant from the Food and Drug Administration (grant number: No. 75F40119C10068).</p></sec><sec sec-type="COI-statement" id="psp413276-sec-0025"><title>CONFLICT OF INTEREST STATEMENT</title><p>J.V.S.G. is a co&#8208;founder of Pumas&#8208;AI, which commercializes Pumas software. All other authors declared no competing interests for this work.</p></sec><sec id="psp413276-sec-0026"><title>Disclaimer</title><p>The opinions expressed in this article are those of the authors and should not be interpreted as the position of the US Food and Drug Administration.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="psp413276-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-14-331-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="psp413276-sec-0023"><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank all their collaborators in the project &#8220;Batch&#8208;to&#8208;Batch Variability of Advair: Exploring Solutions for Generic BE Pathway&#8221; under the FDA contract 75F40119C10068.</p></ack><ref-list content-type="cited-references" id="psp413276-bibl-0001"><title>REFERENCES</title><ref id="psp413276-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0001"><article-title>Asthma facts and figures</article-title>. Accessed September 26, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aafa.org/asthma-facts/" ext-link-type="uri">https://www.aafa.org/asthma&#8208;facts/</ext-link></mixed-citation></ref><ref id="psp413276-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="psp413276-cit-0002"><string-name name-style="western"><surname>Aalbers</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Vogelmeier</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kuna</surname><given-names>P</given-names></string-name>. <article-title>Achieving asthma control with ICS/LABA: a review of strategies for asthma management and prevention</article-title>. <source>Respir Med</source>. <year>2016</year>;<volume>111</volume>:<fpage>1</fpage>&#8208;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.RMED.2015.11.002</pub-id><pub-id pub-id-type="pmid">26614594</pub-id></mixed-citation></ref><ref id="psp413276-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="psp413276-cit-0003"><string-name name-style="western"><surname>Burmeister Getz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></string-name>. <article-title>Batch&#8208;to&#8208;batch pharmacokinetic variability confounds current bioequivalence regulations: a dry powder inhaler randomized clinical trial</article-title>. <source>Clin Pharmacol Ther</source>. <year>2016</year>;<volume>100</volume>(<issue>3</issue>):<fpage>223</fpage>&#8208;<lpage>231</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.373</pub-id><pub-id pub-id-type="pmid">27037630</pub-id><pub-id pub-id-type="pmcid">PMC5102576</pub-id></mixed-citation></ref><ref id="psp413276-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="psp413276-cit-0004"><string-name name-style="western"><surname>Teper</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>D</given-names></string-name>. <article-title>Safety of adding salmeterol to fluticasone propionate in children with asthma</article-title>. <source>Arch Argent Pediatr</source>. <year>2017</year>;<volume>115</volume>(<issue>1</issue>):<fpage>e53</fpage>&#8208;<lpage>e54</lpage>. doi:<pub-id pub-id-type="doi">10.1056/nejmoa1606356</pub-id></mixed-citation></ref><ref id="psp413276-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0005"><article-title>Advair Diskus Label</article-title>. Accessed February 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021077s029lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021077s029lbl.pdf</ext-link></mixed-citation></ref><ref id="psp413276-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="psp413276-cit-0006"><string-name name-style="western"><surname>Kirby</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Falcoz</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Daniel</surname><given-names>MJ</given-names></string-name>, et&#160;al. <article-title>Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2001</year>;<volume>56</volume>(<issue>11</issue>):<fpage>781</fpage>&#8208;<lpage>791</lpage>. doi:<pub-id pub-id-type="doi">10.1007/S002280000233</pub-id><pub-id pub-id-type="pmid">11294367</pub-id></mixed-citation></ref><ref id="psp413276-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="psp413276-cit-0007"><string-name name-style="western"><surname>Mackie</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Bye</surname><given-names>A</given-names></string-name>. <article-title>The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers</article-title>. <source>Clin Pharmacokinet</source>. <year>2000</year>;<volume>39</volume>(<issue>Suppl. 1</issue>):<fpage>47</fpage>&#8208;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00003088-200039001-00007</pub-id><pub-id pub-id-type="pmid">11140433</pub-id></mixed-citation></ref><ref id="psp413276-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="psp413276-cit-0008"><string-name name-style="western"><surname>Maconochie</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Forster</surname><given-names>J</given-names></string-name>. <article-title>Dose&#8208;response study with high&#8208;dose inhaled salmeterol in healthy subjects</article-title>. <source>Br J Clin Pharmacol</source>. <year>1992</year>;<volume>33</volume>(<issue>3</issue>):<fpage>342</fpage>&#8208;<lpage>345</lpage>. doi:<pub-id pub-id-type="doi">10.1111/J.1365-2125.1992.TB04049.X</pub-id><pub-id pub-id-type="pmid">1349491</pub-id><pub-id pub-id-type="pmcid">PMC1381289</pub-id></mixed-citation></ref><ref id="psp413276-bib-0009"><label>9</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0009"><article-title>In fight for GSK's Advair, generic firms step carefully on price</article-title>. Accessed September 26, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/article/us-gsk-advair/in-fight-for-gsks-advair-generic-firms-step-carefully-on-price-idUSKCN0YP1E0" ext-link-type="uri">https://www.reuters.com/article/us&#8208;gsk&#8208;advair/in&#8208;fight&#8208;for&#8208;gsks&#8208;advair&#8208;generic&#8208;firms&#8208;step&#8208;carefully&#8208;on&#8208;price&#8208;idUSKCN0YP1E0</ext-link></mixed-citation></ref><ref id="psp413276-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0010"><article-title>Use of salmeterol and fluticasone propionate combination patent</article-title>. Accessed September 26, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://patentimages.storage.googleapis.com/d5/6f/bc/968e2adbe3b29a/US20040009963A1.pdf" ext-link-type="uri">https://patentimages.storage.googleapis.com/d5/6f/bc/968e2adbe3b29a/US20040009963A1.pdf</ext-link></mixed-citation></ref><ref id="psp413276-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0011"><article-title>The 10 most&#8208;prescribed and top&#8208;selling medications</article-title>. Accessed September 26, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.webmd.com/drug-medication/news/20150508/most-prescribed-top-selling-drugs" ext-link-type="uri">https://www.webmd.com/drug&#8208;medication/news/20150508/most&#8208;prescribed&#8208;top&#8208;selling&#8208;drugs</ext-link></mixed-citation></ref><ref id="psp413276-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0012"><article-title>Inhalation device patent</article-title>. Accessed September 26, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://patentimages.storage.googleapis.com/pdfs/3f6538faa93a1078a914/US5873360.pdf" ext-link-type="uri">https://patentimages.storage.googleapis.com/pdfs/3f6538faa93a1078a914/US5873360.pdf</ext-link></mixed-citation></ref><ref id="psp413276-bib-0013"><label>13</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0013"><article-title>Wixela package insert</article-title>. <year>2020</year>. Accessed September 26, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208891Orig1s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208891Orig1s000lbl.pdf</ext-link></mixed-citation></ref><ref id="psp413276-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="psp413276-cit-0014"><string-name name-style="western"><surname>Haughie</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Allan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>J</given-names></string-name>. <article-title>Equivalent systemic exposure to fluticasone propionate/salmeterol following single inhaled doses from advair diskus and wixela inhub: results of three pharmacokinetic bioequivalence studies</article-title>. <source>J Aerosol Med Pulm Drug Deliv</source>. <year>2019</year>;<volume>33</volume>:<fpage>34</fpage>&#8208;<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1089/jamp.2019.1537</pub-id><pub-id pub-id-type="pmid">31364911</pub-id><pub-id pub-id-type="pmcid">PMC7041328</pub-id></mixed-citation></ref><ref id="psp413276-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="psp413276-cit-0015"><string-name name-style="western"><surname>Ng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kerwin</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>M</given-names></string-name> v., et&#160;al. <article-title>Clinical bioequivalence of Wixela Inhub and Advair Diskus in adults with asthma</article-title>. <source>J Aerosol Med Pulm Drug Deliv</source><year>2020</year>;<volume>33</volume>(<issue>2</issue>):<fpage>99</fpage>&#8211;<lpage>107</lpage>. doi:<pub-id pub-id-type="doi">10.1089/JAMP.2019.1547</pub-id><pub-id pub-id-type="pmid">31634023</pub-id><pub-id pub-id-type="pmcid">PMC7133441</pub-id></mixed-citation></ref><ref id="psp413276-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0016"><collab collab-type="authors">FDA</collab>
. <article-title>Generic competition and drug prices</article-title>. Accessed September 26, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices" ext-link-type="uri">https://www.fda.gov/about&#8208;fda/center&#8208;drug&#8208;evaluation&#8208;and&#8208;research&#8208;cder/generic&#8208;competition&#8208;and&#8208;drug&#8208;prices</ext-link></mixed-citation></ref><ref id="psp413276-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="psp413276-cit-0017"><string-name name-style="western"><surname>Laba</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Jan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zwar</surname><given-names>NA</given-names></string-name>, et&#160;al. <article-title>Cost&#8208;related underuse of medicines for asthma&#8208;opportunities for improving adherence</article-title>. <source>J Allergy Clin Immunol Pract</source>. <year>2019</year>;<volume>7</volume>(<issue>7</issue>):<fpage>2298</fpage>&#8208;<lpage>2306.e12</lpage>. doi:<pub-id pub-id-type="doi">10.1016/J.JAIP.2019.03.024</pub-id><pub-id pub-id-type="pmid">30928659</pub-id></mixed-citation></ref><ref id="psp413276-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="psp413276-cit-0018"><string-name name-style="western"><surname>Stern</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Berman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lumry</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data</article-title>. <source>Ann Allergy Asthma Immunol</source>. <year>2006</year>;<volume>97</volume>(<issue>3</issue>):<fpage>402</fpage>&#8208;<lpage>408</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1081-1206(10)60808-3</pub-id><pub-id pub-id-type="pmid">17042149</pub-id></mixed-citation></ref><ref id="psp413276-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0019"><collab collab-type="authors">United States Food and Drug Administration</collab>
. <article-title>Guidance on fluticasone propionate; salmeterol xinafoate</article-title>. <italic toggle="yes">US Food and Drug Administration</italic>. Published online 2013:2&#8211;8. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/FluticasoneProprionate_SalmeterolXinafoate_21077_RC09-13.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/FluticasoneProprionate_SalmeterolXinafoate_21077_RC09&#8208;13.pdf</ext-link></mixed-citation></ref><ref id="psp413276-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="psp413276-cit-0020"><string-name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></string-name>, <string-name name-style="western"><surname>Jayachandran</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Burmeister</surname><given-names>GE</given-names></string-name>. <article-title>Batch&#8208;to&#8208;batch and within&#8208;subject variability: what do we know and how do these variabilities affect clinical pharmacology and bioequivalence?</article-title><source>Clin Pharmacol Ther</source>. <year>2019</year>;<volume>105</volume>(<issue>2</issue>):<fpage>326</fpage>&#8208;<lpage>328</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.1294</pub-id><pub-id pub-id-type="pmid">30652313</pub-id></mixed-citation></ref><ref id="psp413276-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="psp413276-cit-0021"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Pharmacokinetic models for inhaled fluticasone propionate and Salmeterol Xinafoate to quantify batch&#8208;to&#8208;batch variability</article-title>. <source>AAPS J</source>. <year>2024</year>;<volume>26</volume>(<issue>3</issue>):<fpage>56</fpage>. doi:<pub-id pub-id-type="doi">10.1208/S12248-024-00913-X</pub-id><pub-id pub-id-type="pmid">38671158</pub-id></mixed-citation></ref><ref id="psp413276-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0022"><collab collab-type="authors">FDA</collab>
. <article-title>Statistical approaches to establishing bioequivalence</article-title>. Accessed September 26, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence" ext-link-type="uri">https://www.fda.gov/regulatory&#8208;information/search&#8208;fda&#8208;guidance&#8208;documents/statistical&#8208;approaches&#8208;establishing&#8208;bioequivalence</ext-link></mixed-citation></ref><ref id="psp413276-bib-0023"><label>23</label><mixed-citation publication-type="miscellaneous" id="psp413276-cit-0023"><string-name name-style="western"><surname>Rackauckas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Noack</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Accelerated predictive healthcare analytics with pumas, a high performance pharmaceutical modeling and simulation platform</article-title>. <italic toggle="yes">bioRxiv</italic>. Published online March 20, 2022:2020.11.28.402297. doi:<pub-id pub-id-type="doi">10.1101/2020.11.28.402297</pub-id></mixed-citation></ref><ref id="psp413276-bib-0024"><label>24</label><mixed-citation publication-type="book" id="psp413276-cit-0024"><collab collab-type="authors">R Core Team</collab>
. <source>R A Language and Environment for Statistical Computing</source>. <publisher-name>R Foundation for Statistical Computing</publisher-name>; <year>2018</year>. References &#8208; Scientific Research Publishing. Accessed June 5, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.scirp.org/(S(lz5mqp453edsnp55rrgjct55))/reference/ReferencesPapers.aspx?ReferenceID=2342186" ext-link-type="uri">https://www.scirp.org/(S(lz5mqp453edsnp55rrgjct55))/reference/ReferencesPapers.aspx?ReferenceID=2342186</ext-link></mixed-citation></ref><ref id="psp413276-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="psp413276-cit-0025"><string-name name-style="western"><surname>Yu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Fioritto</surname><given-names>AF</given-names></string-name>, et&#160;al. <article-title>Measurement of in&#160;vivo gastrointestinal release and dissolution of three locally acting Mesalamine formulations in regions of the human gastrointestinal tract</article-title>. <source>Mol Pharm</source>. <year>2017</year>;<volume>14</volume>(<issue>2</issue>):<fpage>345</fpage>&#8208;<lpage>358</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ACS.MOLPHARMACEUT.6B00641</pub-id><pub-id pub-id-type="pmid">28009518</pub-id></mixed-citation></ref><ref id="psp413276-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="psp413276-cit-0026"><string-name name-style="western"><surname>Lionberger</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Raw</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>LX</given-names></string-name>. <article-title>Use of partial AUC to demonstrate bioequivalence of zolpidem tartrate extended release formulations</article-title>. <source>Pharm Res</source>. <year>2012</year>;<volume>29</volume>(<issue>4</issue>):<fpage>1110</fpage>&#8208;<lpage>1120</lpage>. doi:<pub-id pub-id-type="doi">10.1007/S11095-011-0662-8</pub-id><pub-id pub-id-type="pmid">22278753</pub-id></mixed-citation></ref><ref id="psp413276-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="psp413276-cit-0027"><string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Makhlouf</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Schuirmann</surname><given-names>DJ</given-names></string-name>, et&#160;al. <article-title>A bioequivalence approach for generic narrow therapeutic index drugs: evaluation of the reference&#8208;scaled approach and variability comparison criterion</article-title>. <source>AAPS J</source>. <year>2015</year>;<volume>17</volume>(<issue>4</issue>):<fpage>891</fpage>&#8208;<lpage>901</lpage>. doi:<pub-id pub-id-type="doi">10.1208/S12248-015-9753-5</pub-id><pub-id pub-id-type="pmid">25840883</pub-id><pub-id pub-id-type="pmcid">PMC4476992</pub-id></mixed-citation></ref><ref id="psp413276-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="psp413276-cit-0028"><string-name name-style="western"><surname>Burmeister Getz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Mielke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>B</given-names></string-name>. <article-title>Between&#8208;batch pharmacokinetic variability inflates type I error rate in conventional bioequivalence trials: a randomized Advair Diskus clinical trial</article-title>. <source>Clin Pharmacol Ther</source>. <year>2017</year>;<volume>101</volume>(<issue>3</issue>):<fpage>331</fpage>&#8208;<lpage>340</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.535</pub-id><pub-id pub-id-type="pmid">27727445</pub-id><pub-id pub-id-type="pmcid">PMC5324827</pub-id></mixed-citation></ref><ref id="psp413276-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="psp413276-cit-0029"><string-name name-style="western"><surname>Hochhaus</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Horhota</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hendeles</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Suarez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rebello</surname><given-names>J</given-names></string-name>. <article-title>Pharmacokinetics of orally inhaled drug products</article-title>. <source>AAPS J</source>. <year>2015</year>;<volume>17</volume>(<issue>3</issue>):<fpage>769</fpage>&#8208;<lpage>775</lpage>. doi:<pub-id pub-id-type="doi">10.1208/s12248-015-9736-6</pub-id><pub-id pub-id-type="pmid">25762449</pub-id><pub-id pub-id-type="pmcid">PMC4406971</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>